Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptic vesicle protein 2 (SV2) and Synaptotagmin (Syt) are integral membrane proteins located on the luminal surface of synaptic vesicles within presynaptic nerve terminals. They serve as the high-affinity protein receptors for Botulinum neurotoxins (BoNTs), which are potent inhibitors of neurotransmitter release (Dong et al., 2006). SV2 isoforms (A, B, and C) are the primary receptors for BoNT/A, BoNT/D, BoNT/E, and BoNT/F, while Synaptotagmin I and II serve as receptors for BoNT/B and BoNT/G (Dong et al., 2003). Upon binding to these receptors during the process of vesicle recycling, the toxins are internalized via endocytosis into cholinergic neurons. Once inside, the light chain of the toxin is translocated into the cytosol, where it cleaves specific SNARE proteins (such as SNAP-25 or VAMP), effectively blocking the release of acetylcholine at the neuromuscular junction (Pirazzini et al., 2017). This mechanism is exploited therapeutically to treat conditions characterized by muscle overactivity, such as dystonia and spasticity, as well as chronic migraine and hyperhidrosis (StatPearls, 2023).
Botulinum neurotoxins bind to the luminal domains of SV2 or Synaptotagmin during vesicle recycling, facilitating their internalization into the presynaptic terminal where they subsequently cleave SNARE proteins to inhibit acetylcholine release.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptic vesicle protein 2 and Synaptotagmin (SV2/Syt).